Covi

Chimney Selected to Present its Newest Product, Chimney Home at NACUSO’s 2024 Next Big Idea Competition

Retrieved on: 
Tuesday, April 16, 2024
Software, Construction & Property, Finance, Banking, Professional Services, Technology, Fintech, Residential Building & Real Estate, Covi, Zillow, Conference

Chimney , an award-winning fintech provider for over 65 credit unions, was selected as one of six companies to compete in NACUSO’s annual Next Big Idea Competition , which will take place at the NACUSO Network Conference on April 17, 2024 in Orlando, FL.

Key Points: 
  • Chimney , an award-winning fintech provider for over 65 credit unions, was selected as one of six companies to compete in NACUSO’s annual Next Big Idea Competition , which will take place at the NACUSO Network Conference on April 17, 2024 in Orlando, FL.
  • Matthew Covi, co-founder and CEO of Chimney, will present the company’s latest innovation, Chimney Home, which revolutionizes how financial institutions tap property data in their digital apps.
  • "Homes are the most valuable asset for most credit union members," said Covi.
  • With Chimney Home, homeowners can get personalized information, insights and offers, right within their mobile banking app.

Covis Announces Signing of Support Agreements With Its Lenders and Equity Sponsors, Leading to a Material Strengthening of Its Financial Position, Including the Elimination of ~$450 Million of Debt

Retrieved on: 
Monday, April 3, 2023
PJT Partners, Recapitalization, Support, Apollo Global Management, Mortgage law, Paul, Weiss, Rifkind, Wharton & Garrison, Health, Berkeley Research Group, Weil, Gotshal & Manges, Credit, Financial adviser, Covi

ZUG, Switzerland, April 03, 2023 (GLOBE NEWSWIRE) -- Covis Finco Sarl (together with its subsidiaries “Covis” or the “Company”), today announced that the Company entered into the Support Agreement with its Equity Sponsors, approximately 95% of its First Lien Lenders (including Revolving Facility Lenders) and 100% of its Second Lien Lenders regarding the terms of a comprehensive financial recapitalization that will reduce its debt by ~$450 million (the “Recapitalization”). The Recapitalization leads to a material strengthening of Covis’ balance sheet as well as its liquidity position. Upon consummation of the Recapitalization, funds managed by an affiliate of Apollo Global Management (the “Equity Sponsors”) will remain majority owners of the Company, while the First Lien Lenders will receive a significant minority stake.

Key Points: 
  • The Recapitalization leads to a material strengthening of Covis’ balance sheet as well as its liquidity position.
  • Covis will also pursue inorganic growth opportunities, which have historically been a key value lever for the Company.
  • To implement the Recapitalization, the Company is soliciting approval from its lenders of the transactions contemplated by the Support Agreement.
  • Covis expects to complete this process quickly and efficiently and, with the strong support of its Equity Sponsors and lenders, anticipates a near-term closing of the Recapitalization.

Covis Enters Promotion and Distribution Agreement for Two Respiratory Medicines, Seebri® Breezhaler® and Ultibro® Breezhaler®, in Canada

Retrieved on: 
Wednesday, January 5, 2022
LAMA, Respiratory disease, Distribution, Acquisition, Head, Patient, AstraZeneca, Asthma, Allergic rhinitis, Covi, Capsule, LABA, Chronic obstructive pulmonary disease, GLOBE, COPD, Generic drug, Health insurance, Pharmaceutical industry

Used for the treatment of chronic obstructive pulmonary disease (COPD), these medicines add to Covis current Canadian respiratory offering.

Key Points: 
  • Used for the treatment of chronic obstructive pulmonary disease (COPD), these medicines add to Covis current Canadian respiratory offering.
  • COPD is a common illness, affecting over 830,000 people over 35 years of age in Canada in 20201.
  • This agreement for Covis Canada to be the exclusive promotion and distribution partner for Seebri Breezhaler and Ultibro Breezhaler is effective January 1, 2022 and will continue for an initial term of seven years.
  • Ultibro Breezhaler (indacaterol maleate/glycopyrronium bromide) is a combination therapy that contains both a LAMA and a long-acting beta2-agonist (LABA).

Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca

Retrieved on: 
Wednesday, January 5, 2022
LAMA, Sidley Austin, Respiratory disease, Buchanan Ingersoll & Rooney, Distribution, Acquisition, Novartis, Paul, Weiss, Rifkind, Wharton & Garrison, Growth, Inhalation, Barclays, Patient, Gesellschaft mit beschränkter Haftung, Asthma, Allergic rhinitis, Partnership, LABA, GLOBE, COPD, Maintenance, Pharmaceutical industry, AstraZeneca, Covi

Under the terms of the Acquisition agreement, AstraZeneca received a payment of $270m from Covis.

Key Points: 
  • Under the terms of the Acquisition agreement, AstraZeneca received a payment of $270m from Covis.
  • AstraZeneca will also receive payments in respect of certain ongoing development costs related to the medicines.
  • As previously announced, as a result of the acquisition and this partnership with Novartis, Covis is firmly placed as one of the top 10 respiratory companies in the world.
  • In connection with the Acquisition, Barclays acted as financial advisor to Covis and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to Covis.

Matthew Covi, Signal Intent CEO and Co-founder, Named a 2021 Lending Luminary by PROGRESS in Lending Association

Retrieved on: 
Wednesday, October 20, 2021
Professional Services, Communications, Technology, Search Engine Optimization, Other Technology, Finance, Banking, Acquisition, Association, Income, Covi, Trust, Leadership, Intention, Insurance, Industry, Financial technology, PROGRESS, Real estate

Signal Intent, a leader in financial calculators for the digital age, announced today that its CEO and co-founder Matthew Covi has been named a 2021 Lending Luminary by PROGRESS in Lending Association.

Key Points: 
  • Signal Intent, a leader in financial calculators for the digital age, announced today that its CEO and co-founder Matthew Covi has been named a 2021 Lending Luminary by PROGRESS in Lending Association.
  • Under Covis direction, Signal Intent is creating mortgage calculators that build trust and increase engagement.
  • Every homebuyers situation is unique from their income levels to their real estate preferences, to their credit backgrounds.
  • The company delivers modern, digital tools that help banks and lenders compete in todays landscape, including the current ultra-competitive mortgage lending environment.

Signal Intent Selected to Demo at FinovateFall 2021 for Second Time After Winning “Best of Show” at Spring Event

Retrieved on: 
Thursday, September 9, 2021
Finance, Banking, Professional Services, Technology, Software

Signal Intent, a leader in financial calculators for the digital age and winner of the FinovateSpring 2021 Best of Show, has been selected for a second consecutive time to present at FinovateFall 2021, which takes place September 13-15 in New York.

Key Points: 
  • Signal Intent, a leader in financial calculators for the digital age and winner of the FinovateSpring 2021 Best of Show, has been selected for a second consecutive time to present at FinovateFall 2021, which takes place September 13-15 in New York.
  • In fact, research shows that having at least one calculator for key products helps increase traffic and improves a financial institutions funnel.
  • Signal Intent empowers financial institutions and lenders through calculators that drive leads and unlock personalized customer experiences.
  • New York-based Signal Intent is transforming the way financial institutions guide customers through their buying journey.

Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July

Retrieved on: 
Thursday, June 24, 2021
Typography, Typefaces, Writing systems, Sorrento, STIX Fonts project, Covi, Stix

Sorrento received official EUA registration and product import license: COFEPRIS EUA registration number OFICIO: CAS/10720/2021.

Key Points: 
  • Sorrento received official EUA registration and product import license: COFEPRIS EUA registration number OFICIO: CAS/10720/2021.
  • Sorrento is establishing its Sorrento Mexico Ltd subsidiary to enable commercialization of COVI-STIX and future COVID-19 related products in the country.
  • Sorrento expects the first shipments for initial COVI-STIX test orders to be delivered in July.
  • Sorrento will commercially launch the COVI-STIX test in Mexico with the first shipments expected to be delivered in July.

Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests

Retrieved on: 
Wednesday, June 2, 2021
Video games, Video game platforms, Home computer games, Biostatistics, Medical statistics, Sorrento, Sensitivity, Covi, Qix

Sorrento has initiated importation and commercial roll-out activities for Mexico and expects the product to be commercially available in-market within weeks.

Key Points: 
  • Sorrento has initiated importation and commercial roll-out activities for Mexico and expects the product to be commercially available in-market within weeks.
  • Among all the products listed currently, COVI-STIX outperformed for both Sensitivity (91.89%) and Specificity (99.23%).
  • With todays approval, Sorrento is able to offer a high quality and affordable diagnostic solution for Mexico.
  • We look forward to working even more closely with the Mexican government to help deploy our test at scale.

Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference

Retrieved on: 
Friday, March 5, 2021
Arthritis, Radicular pain, Osteoarthritis, Covi, Antiviral drug, Biology

Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.

Key Points: 
  • Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.
  • SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.
  • ZTlido was approved by the FDA on February 28, 2018.

Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021

Retrieved on: 
Tuesday, January 19, 2021
Health sciences, Life sciences, Applied sciences, Covi, Drug discovery, Radicular pain, Antiviral drug, Osteoarthritis, Therapy

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers.

Key Points: 
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers.
  • Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC and COVI-DROPS; and diagnostic test solutions, including COVI-TRACK, COVI-STIX and COVI-TRACE.
  • RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.
  • SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.